Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study

Blood blood.2024025746.

https://doi.org/10.1182/blood.2024025746

Published: 2024

Includes: Supplemental data

Journal Articles

A Phase 2 Study of Nivolumab for Relapsed/Refractory Multiple Myeloma or Non-Hodgkin Lymphoma Following CAR-T Therapy

Blood (2023) 142 (Supplement 1): 3509.

https://doi.org/10.1182/blood-2023-173202

Published: 2023

Journal Articles

Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study

Blood (2023) 142 (Supplement 1): 4746.

https://doi.org/10.1182/blood-2023-177968

Published: 2023

Journal Articles

Health-Related Quality of Life (HRQoL) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1: Interim Assessment up to 36 Weeks of Treatment

Blood (2023) 142 (Supplement 1): 3359.

https://doi.org/10.1182/blood-2023-179170

Published: 2023

Journal Articles

Optimal Sequencing Determination in Relapsed Multiple Myeloma

Salyka M. Sengsayadeth, Bridget Fitzgerald, Bharat Nandakumar, Bicky Thapa, Timothy Martin Schmidt, Rebecca Silbermann, Heidi Chen, Saurabh Chhabra, Natalie Callander, Shaji K Kumar, Luciano J. Costa

Blood (2022) 140 (Supplement 1): 10033–10035.

https://doi.org/10.1182/blood-2022-169589

Published: 2022

Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) Who Are Triple-Class Exposed to an Immunomodulatory Agent, a Proteasome Inhibitor, and an Anti-CD38 Antibody

Nina Shah, Ravi Vij, Jenna S. Roberts, Ivana Rajkovic, Rebecca Silbermann, Jens Hillengass, Sujith Dhanasiri, Julia Braverman, Abigail McMillan, Devender Dhanda

Blood (2022) 140 (Supplement 1): 13259–13261.

https://doi.org/10.1182/blood-2022-158235

Published: 2022

Journal Articles

Outcomes of MRD-Adapted Treatment Modulation in Patients with Newly Diagnosed Multiple Myeloma Receiving Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) and Autologous Transplantation: Extended Follow up of the Master Trial

Luciano J. Costa, Saurabh Chhabra, Eva Medvedova, Timothy Martin Schmidt, Bhagirathbhai Dholaria, Kelly N. Godby, Rebecca Silbermann, Susan Bal, Anita D'Souza, Smith Giri, James L. Omel, Parameswaran Hari, Natalie Callander, Binod Dhakal

Blood (2022) 140 (Supplement 1): 7275–7277.

https://doi.org/10.1182/blood-2022-156730

Published: 2022

Journal Articles

Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies

Blood (2022) 140 (Supplement 1): 10144–10147.

https://doi.org/10.1182/blood-2022-160451

Published: 2022

Journal Articles

Humoral Immune Reconstitution Following Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Hematopoietic Cell Transplantation (AHCT) and MRD-Response-Adapted Treatment Cessation

Timothy Martin Schmidt, Rebecca Silbermann, Susan Bal, Binod Dhakal, Bhagirathbhai Dholaria, Eden Biltibo, Saurabh Chhabra, Smith Giri, Kelly N. Godby, Sonia Gowda, Eva Medvedova, Natalie Callander, Luciano J. Costa

Blood (2022) 140 (Supplement 1): 10077–10078.

https://doi.org/10.1182/blood-2022-164930

Published: 2022

Journal Articles

Quadruplet Induction, Autologous Transplantation and Minimal Residual Disease Adapted Consolidation and Treatment Cessation in Older Adults ≥70y with Newly Diagnosed Multiple Myeloma: A Subgroup Analysis of the Master Trial

Smith Giri, Saurabh Chhabra, Eva Medvedova, Bhagirathbhai Dholaria, Timothy Martin Schmidt, Kelly N. Godby, Rebecca Silbermann, Binod Dhakal, Susan Bal, Anita D'Souza, Aric C. Hall, Pamela Hardwick, Jim Omel, Robert Frank Cornell, Natalie Callander, Parameswaran Hari, Luciano J. Costa

Blood (2022) 140 (Supplement 1): 4431–4433.

https://doi.org/10.1182/blood-2022-160381

Published: 2022

Journal Articles

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups

Blood (2022) 140 (Supplement 1): 7278–7281.

https://doi.org/10.1182/blood-2022-162339

Published: 2022

Journal Articles

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone: Patient Reported Outcomes from GRIFFIN

Blood (2022) 140 (Supplement 1): 1146–1149.

https://doi.org/10.1182/blood-2022-162313

Published: 2022

Journal Articles

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

Blood (2020) 136 (8): 936–945.

https://doi.org/10.1182/blood.2020005288

Published: 2020

Includes: Supplemental data

Journal Articles

EZH2 Inhibitor GSK126 Exhibits Osteo-Anabolic Properties in MM Bone Disease and Synergizes with Bortezomib to Inhibit MM Cell Viability

Juraj Adamik, PhD, Rebecca Silbermann, MD, Konstantinos Lontos, MD, Peng Zhang, PhD, Quanhong Sun, Deborah Lynn Galson, PhD, G. David Roodman, MD PhD

Blood (2016) 128 (22): 3247.

https://doi.org/10.1182/blood.V128.22.3247.3247

Published: 2016

Journal Articles

p62-ZZ Domain Signaling Inhibition Rescues MM-Induced Epigenetic Repression at the Runx2 promoter and Allows Osteoblast Differentiation of MM Patient Pre-Osteoblasts In Vitro

Rebecca Silbermann, MD, Juraj Adamik, PhD, Dan Zhou, Xiang-Qun Xie, MD PhD EMBA, Noriyoshi Kurihara, DDS, PhD, G. David Roodman, MD PhD, Deborah Lynn Galson, PhD

Blood (2016) 128 (22): 4410.

https://doi.org/10.1182/blood.V128.22.4410.4410

Published: 2016

Journal Articles

p62-ZZ Domain Inhibition Prevents MM Cell-Induced Epigenetic Changes at the Runx2 and C/EBPb Promoters

Rebecca Silbermann, MD, Juraj Adamik, PhD, Dan Zhou, Xiang-Qun Xie, MD PhD EMBA, G. David Roodman, MD PhD, Noriyoshi Kurihara, DDS, PhD, Deborah Lynn Galson, PhD

Blood (2015) 126 (23): 1796.

https://doi.org/10.1182/blood.V126.23.1796.1796

Published: 2015

Journal Articles

Phase I/II Study of Lenalidomide and High Dose Melphalan As Preparative Regimen in Autologous Transplant in Myeloma: Report of Phase II Efficacy and Safety Data

Attaya Suvannasankha, MD, Sherif Farag, MD PhD, Rebecca Silbermann, MD, Mary Cangany, RN, Anita Rush-Taylor, RN, Robin O'Bryant, RN, Lisa Wood, RN, Jean Pearson, Sarah Singleton, Andrea Bradley, Sandra Althouse, Susan Perkins, PhD, Deb Estes, RN, Rafat Abonour, MD

Blood (2015) 126 (23): 3193.

https://doi.org/10.1182/blood.V126.23.3193.3193

Published: 2015

Journal Articles

The p62-ZZ Domain Inhibitor XRK3F2 Alters Myeloma-Induced Suppression of Osteoblast Differentiation and Is Highly Cytotoxic to Myeloma Cells in Combination with Bortezomib

Rebecca Silbermann, MD, Dan Zhou, Jumpei Teramachi, DDS, PhD, Xiang-Qun Xie, PhD, G. David Roodman, MD PhD, Noriyoshi Kurihara, DDS, PhD

Blood (2014) 124 (21): 2083.

https://doi.org/10.1182/blood.V124.21.2083.2083

Published: 2014

Journal Articles

IL3 Induces Osteoclastogenesis In Vivo and Is Modulated By Bone Marrow Monocyte / Macrophage Derived Activin A

Rebecca Silbermann, MD, Marina Bolzoni, Paola Storti, PhD, Daniela Guasco, Judith Anderson, Jolene J. Windle, PhD, G. David Roodman, MD, PhD, Nicola Giuliani, MD, PhD

Blood (2013) 122 (21): 3101.

https://doi.org/10.1182/blood.V122.21.3101.3101

Published: 2013

Journal Articles

A Novel Sequestosome-1/p62 ZZ Domain Inhibitor Induces New Bone Formation In The Presence Of Myeloma In Vivo

Rebecca Silbermann, MD, Wei Zhao, MBBS, Julie L Eiseman, PhD, Jan H Beumer, PharmD, PhD, Xiang-Qun Xie, PhD, Peng Yang, PhD, Kyaw-Zeyar Myint, PhD, Lirong Wang, PhD, Zhiwei Feng, PhD, Jolene J. Windle, PhD, G. David Roodman, MD, PhD, Noriyoshi Kurihara, DDS, PhD

Blood (2013) 122 (21): 684.

https://doi.org/10.1182/blood.V122.21.684.684

Published: 2013

NARROW

Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study

A Phase 2 Study of Nivolumab for Relapsed/Refractory Multiple Myeloma or Non-Hodgkin Lymphoma Following CAR-T Therapy

Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study

Health-Related Quality of Life (HRQoL) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1: Interim Assessment up to 36 Weeks of Treatment

Optimal Sequencing Determination in Relapsed Multiple Myeloma

Health-Related Quality of Life (HRQoL) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) Who Are Triple-Class Exposed to an Immunomodulatory Agent, a Proteasome Inhibitor, and an Anti-CD38 Antibody

Outcomes of MRD-Adapted Treatment Modulation in Patients with Newly Diagnosed Multiple Myeloma Receiving Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) and Autologous Transplantation: Extended Follow up of the Master Trial

Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies

Humoral Immune Reconstitution Following Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Hematopoietic Cell Transplantation (AHCT) and MRD-Response-Adapted Treatment Cessation

Quadruplet Induction, Autologous Transplantation and Minimal Residual Disease Adapted Consolidation and Treatment Cessation in Older Adults ≥70y with Newly Diagnosed Multiple Myeloma: A Subgroup Analysis of the Master Trial

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone: Patient Reported Outcomes from GRIFFIN

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

EZH2 Inhibitor GSK126 Exhibits Osteo-Anabolic Properties in MM Bone Disease and Synergizes with Bortezomib to Inhibit MM Cell Viability

p62-ZZ Domain Signaling Inhibition Rescues MM-Induced Epigenetic Repression at the Runx2 promoter and Allows Osteoblast Differentiation of MM Patient Pre-Osteoblasts In Vitro

p62-ZZ Domain Inhibition Prevents MM Cell-Induced Epigenetic Changes at the Runx2 and C/EBPb Promoters

Phase I/II Study of Lenalidomide and High Dose Melphalan As Preparative Regimen in Autologous Transplant in Myeloma: Report of Phase II Efficacy and Safety Data

The p62-ZZ Domain Inhibitor XRK3F2 Alters Myeloma-Induced Suppression of Osteoblast Differentiation and Is Highly Cytotoxic to Myeloma Cells in Combination with Bortezomib

IL3 Induces Osteoclastogenesis In Vivo and Is Modulated By Bone Marrow Monocyte / Macrophage Derived Activin A

A Novel Sequestosome-1/p62 ZZ Domain Inhibitor Induces New Bone Formation In The Presence Of Myeloma In Vivo

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only